Helix BioPharma Corp. (TSX: HBP, OTC PINK: HBPCD, FRANKFURT: HBP0), a clinical-stage oncology company, announced yesterday that it presented new data on its CEACAM6-directed antibody-drug conjugate (ADC) program at the 16th Annual World ADC London conference. The presentation, titled “Next-Generation ADCs: Unlocking the Potential of CEACAM6-Directed Targeted Therapies,” was delivered by Jonathan Davis, PhD, Director of ADC Discovery at Helix BioPharma, as part of the conference’s Seminar Day program.
The presentation highlighted CEACAM6 as a compelling therapeutic target due to its elevated expression across a broad range of epithelial cancers, its association with poor clinical outcomes, and its limited expression in healthy tissues. Dr. Davis presented data supporting the tumor-selective binding profile of Helix’s proprietary anti-CEACAM6 VHH, a single-domain antibody fragment derived from camelid antibodies (also known as a nanobody), which demonstrated preferential binding to tumor-expressed CEACAM6. This highly selective binding profile supports the development of next-generation ADCs designed to deliver potent therapeutic payloads directly to cancer cells while minimizing off-target effects.
The data builds on the clinical foundation set by Tumor Defense Breaker™ L-DOS47, Helix’s lead CEACAM6-targeted candidate, which has shown favorable safety and encouraging clinical activity in Phase I/II studies in non-small cell lung cancer (NSCLC). L-DOS47 is an antibody-enzyme conjugate designed to prime CEACAM6-expressing tumors for increased sensitivity to therapy. The new ADC program leverages the same CEACAM6-targeting approach but uses a VHH format that provides enhanced tumor selectivity.
“CEACAM6 represents a compelling and underexploited target with broad potential across multiple hard-to-treat cancers,” said Dr. Davis. “Our proprietary VHH-based targeting approach enables highly selective tumor binding, supporting the development of next-generation ADCs designed to maximize therapeutic impact while minimizing off-target effects. Our presentation generated strong interest and discussion among conference participants, reflecting the growing recognition of CEACAM6 as an important emerging target in oncology.”
A copy of Dr. Davis’ presentation is available on the Company’s website under the “Events and Presentations” page at https://helixbiopharma.com/wp-content/uploads/2026/02/Unlocking-the-Potential-of-CEACAM6.pdf.
World ADC London is a global, annual conference dedicated to the discovery, development, and commercialization of antibody-drug conjugates. Now in its 16th year, it is the longest-standing and one of the leading global conferences dedicated to ADC research and development. The event brings together more than 700 industry stakeholders from over 240 companies, including biopharma organizations, clinicians, investors, and regulatory experts. More information about the conference can be found at https://worldadc-europe.com/.
Helix BioPharma is an oncology company that innovates from strength to bring near-term solutions for today’s hardest-to-treat cancers. The Company’s pipeline is led by Tumor Defense Breaker™ L-DOS47 and includes next-generation bi-specific antibody-drug conjugates (ADCs), currently in discovery. The Company also advances two pre-IND candidates: LEUMUNA™, an oral immune checkpoint modulator, and GEMCEDA™, a first-in-class oral gemcitabine prodrug. For more information, visit https://www.helixbiopharma.com/.
